RECRUITING

Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

International retrospective observational cohort study aimed to describe a molecular classification for NMZL.

Official Title

Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Quick Facts

Study Start:2023-12-31
Study Completion:2026-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05700149

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Male or female adults 18 years or older
  2. 2. Diagnosis of NMZL on lymph node histology after Jan 1st, 2000
  3. 3. Availability of tumor material from lymph node (either frozen or FFPE) collected when the patient was treatment naïve
  4. 4. Availability of the baseline and follow-up annotations
  1. 1. Nodal spread of a clinically occult extranodal MZL (this must have been ruled out by carefully evaluating the extranodal tissues draining to the involved lymph nodes by imaging or endoscopy)

Contacts and Locations

Study Contact

IELSG - Study Coordination Office
CONTACT
+41586667321
ielsg@ior.usi.ch
Davide Rossi, MD
CONTACT
+41918118540
davide.rossi@eoc.ch

Principal Investigator

Davide Rossi, MD
STUDY_CHAIR
Oncology Institute of Southern Switzerland and Institute of Oncology Research

Study Locations (Sites)

University of Miami
Miami, Florida, 33136
United States
Weill Cornell Medical
New York, New York, 10065
United States

Collaborators and Investigators

Sponsor: International Extranodal Lymphoma Study Group (IELSG)

  • Davide Rossi, MD, STUDY_CHAIR, Oncology Institute of Southern Switzerland and Institute of Oncology Research

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-12-31
Study Completion Date2026-12-31

Study Record Updates

Study Start Date2023-12-31
Study Completion Date2026-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Nodal Marginal Zone Lymphoma